8:30 AM8:39 AMHigh prevalence of Bleeding Disorder of Unknown Cause in women: findings from the Maastricht Bleeding Cohort Add to my agenda
8:39 AM8:48 AMJoint health in participants with hemophilia A or B with inhibitors treated with marstacimab in the phase 3 BASIS trial Add to my agenda
8:48 AM8:57 AMMim8 prophylaxis in children with haemophilia A: 52-week efficacy and safety outcomes from FRONTIER3 Add to my agenda
8:57 AM9:06 AMWFH, EAHAD, and EHC: Best Practice Recommendations for Implementing Shared Decision Making in HemophiliaDonna CoffinWorld Federation of Haemophilia Add to my agenda
9:06 AM9:15 AMDurable bleed protection for all bleeding subtypes and favorable safety over 5 years (end-of-study) in the Phase 3 HOPE-B trial for persons with severe or moderately severe Haemophilia BFrank LEEBEEKErasmus University Medical Center Add to my agenda
9:15 AM9:24 AMStable Factor IX Expression and Sustained Reductions in Factor IX Use 9 Years after Gene Therapy with CSL220 in Adults with Haemophilia B Add to my agenda
9:24 AM9:33 AMSubcutaneous Four-Week Dosing of the Novel Protein S Antibody VGA039 Demonstrates Safety and Clinically Meaningful Bleed Reduction in Patients with Von Willebrand Disease: Phase 1/2 Multi-Dose Study ResultsGabriela Yamaguti-HayakawaUniversity of Campinas Add to my agenda
9:33 AM9:42 AMRecombinant von Willebrand Factor Prophylaxis for Severe von Willebrand Disease: Final Results Focusing on Adults Receiving Once Weekly Prophylaxis in a Phase 3b Continuation Study Add to my agenda
9:42 AM9:51 AMSafety, Pharmacodynamics, and Efficacy of NXT007 After Switching from Emicizumab in Hemophilia A with and without inhibitors (NXTAGE Part C) Add to my agenda
9:51 AM10:00 AMCharacterization of ALT elevations during the 5-year GENEr8-1 trial of valoctocogene roxaparvovec gene transfer for severe hemophilia ARobert KLAMROTHVivantes Klinikum im Friedrichshain Add to my agenda
